*Gulp* Much to the relief of the needle-shy, the FDA has just approved a second oral GLP-1 drug, following the release of the semaglutide Wegovy pill in January. But this new tablet, from pharma giant Eli Lilly,

The FDA has approved Foundayo, a new oral obesity drug from Eli Lilly and the second GLP‑1 pill to reach the U.S. market.

Foundayo, developed by drug maker Eli Lilly, represents a major shift in obesity treatment, since it is now the second GLP-1 therapy now approved for obesity as a pill, in addition to the oral wegovy ...